348 A phase 2 umbrella study of retifanlimab (INCMGA00012) alone or in combination with other therapies in patients with advanced or metastatic endometrial cancer (POD1UM-204, GOG 3038, ENGOT-en12/NOGGO)

التفاصيل البيبلوغرافية
العنوان:	348 A phase 2 umbrella study of retifanlimab (INCMGA00012) alone or in combination with other therapies in patients with advanced or metastatic endometrial cancer (POD1UM-204, GOG 3038, ENGOT-en12/NOGGO)
المؤلفون:	Brian Slomovitz, Bradley Monk, Katherine Moxley, Nadeem Ghali, Justyna Fronczek Sokol
المصدر:	Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
بيانات النشر:	BMJ Publishing Group, 2020.
سنة النشر:	2020
المجموعة:	LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
مصطلحات موضوعية:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
نوع الوثيقة:	article
وصف الملف:	electronic resource
اللغة:	English
تدمد:	2051-1426
Relation:	https://doaj.org/toc/2051-1426
DOI:	10.1136/jitc-2020-SITC2020.0348
URL الوصول:	https://doaj.org/article/6cf396afd0874688be83eda1d4eb2662
رقم الأكسشن:	edsdoj.6cf396afd0874688be83eda1d4eb2662
قاعدة البيانات:	Directory of Open Access Journals

الوصف
تدمد:	20511426
DOI:	10.1136/jitc-2020-SITC2020.0348